All posts

Verano is still a Buy, says Haywood

Seasonal softness is expected for the current first quarter but there’s a clear growth runway in front of US cannabis name Verano (Verano Holdings Stock Quote, Charts, News, Analysts, Financials CSE:VRNO), according to Haywood Capital Markets analyst Neal Gilmer, who maintained a “Buy” rating on the stock in a Thursday report.

Active in 13 states across the US and 126 retail locations, Verano is a vertically-integrated cannabis player with 14 production facilities and a stable of brands, including Verano, MÜV and Encore. The company reported its fourth quarter and full 2022 results on Thursday, with Q4 revenue reaching $226 million, good for a year-over-year increase of seven per cent but a one per cent sequential decrease. Adjusted EBITDA for the quarter was $79 million compared to $82 million a year earlier. (All figures in US dollars except where noted otherwise.)

Verano founder, Chairman and CEO George Archos said the lack of movement on legalization at the federal level in the US has been a disappointment recently but state-level momentum has been encouraging. On the company’s growth, Archos noted the addition of over 30 dispensaries across its core markets.

“In 2023, we will consider selective opportunities to further expand our footprint, focus on free cash flow generation, and leverage our leading position in markets that are poised for adult use transition in the near future, including Maryland. I am proud of what we’ve accomplished in just two years since our IPO, and remain excited and confident in our plans to drive long-term, sustainable growth,” Archos wrote.

Gilmer said Verano’s Q4 revenue was in-line with his forecast but adjusted gross margin at 55.3 per cent was below his estimate at 62.0 per cent and down from 64.0 per cent for the prior quarter. Adjusted EBITDA at $78.7 million was above Gilmer’s estimate at $75.7 million and the consensus estimate at $76.9 million. 

Gilmer said on the conference call management spoke of seasonal softness in the current Q1 relative to the Q4 and continued margin pressure. He noted that Verano has joint venture agreements with six social equity dispensary owners in Connecticut that are expected to open stores in 2023 following the launch of adult-use in the state in January and he added that Verano’s position in Maryland continues to strengthen in advance of adult-use sales, which are anticipated to start in the second half of 2023.

“Verano’s footprint is well positioned to capitalize on new growth markets such as Connecticut, Maryland and New Jersey as well as Ohio, Pennsylvania and Florida which are most likely to be the next to pass adult-use. In addition to the growth opportunities, the company has a track record of impressive cost controls required that should enable it to generate meaningful cash flow in its more mature markets,” Gilmer wrote.

With the update, Gilmer retained a 12-month target of C$13.00, which at press time represented a projected return at the time of publication of 238 per cent.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: vrno
Staff

Recent Posts

Is Uber stock a buy? (May, 2024)

Following the release of the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on… [Read More]

2 days ago

Trulieve scores price target raise at Echelon

Following the company's most recent results, Echelon Capital Markets analyst Andrew Semple has raised his price target on Trulieve Cannabis… [Read More]

2 days ago

Is Green Thumb Industries a buy? (May, 2024)

Its first quarter numbers are in the books and Beacon Securities analyst Russell Stanley is still bullish on Green Thumb… [Read More]

3 days ago

Is TKO stock a buy?

Following the company's first quarter results, Roth MKM analyst Eric Handler has maintained his "Buy" rating on TKO Group (TKO… [Read More]

3 days ago

Is WELL Health stock a buy? (May, 2024)

Following the company's first quarter results, Eight Capital analyst Christian Sgro thinks there is a lot of money to be… [Read More]

3 days ago

“You Never Get Fired for Buying Shopify”

Its first quarter results are in the books and ATB Capital Markets analyst Martin Toner has become bullish on Shopify… [Read More]

3 days ago